Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.53 |
| ▸ | KDR | P35968 | 6/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
| ▸ | FLT4 | P35916 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156430 | 0.83 | EGFR (0.61) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL6365282 | 0.81 | EGFR (0.47) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL3136293 | 0.76 | EGFR (0.85) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL30777150 | 0.72 | EGFR (0.38) | EGFRKDRERBB2SRCEPHA2 | |
| SCHEMBL20355385 | 0.72 | EGFR (0.60) | EGFRKDRFLT1KCNH2ERBB2 | |
| SCHEMBL5411253 | 0.69 | KDR (0.61) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL3132716 | 0.69 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL6462110 | 0.69 | KDR (0.62) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL5040071 | 0.68 | EGFR (0.61) | EGFRKDRFLT1FLT4KCNH2 | |
| SCHEMBL4700053 | 0.68 | EGFR (0.46) | EGFRERBB2EPHA2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ABL1, ERBB2, EGFR | EGFR 3/4885KDR 188/4885FGFR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.